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Background: Diamond–Blackfan anemia is a rare congenital red blood cell aplasia characterized by failed
erythropoiesis, congenital abnormalities in up to 50% of patients, growth retardation in up to 30% of patients, and
a predisposition to malignancy. Diamond–Blackfan anemia is both clinically and genetically a heterogenous
condition ranging from subtle asymptomatic erythroid abnormalities to non-immune hydrops fetalis. Current
treatment options include corticosteroid therapy, chronic red blood cell transfusions, and hematopoietic stem cell
transplantation with gene therapy receiving recent attention. We report the first documented case of Diamond–
Blackfan anemia in a Caucasian girl secondary to a sporadic heterozygous whole gene deletion in RPL35A in South
Africa. Limited resources, non-availability of tests, unfamiliarity that comes with rare diseases, an expanded
differential diagnosis, and an associated neutropenia led to a delay in the diagnosis of Diamond–Blackfan anemia.
This case reminds clinicians of Diamond–Blackfan anemia as a cause of aplastic anemia and highlights the difficulty
and obstacles in diagnosing Diamond–Blackfan anemia in resource-limited countries.
Case presentation: We report a case of a 6-week-old Caucasian girl presenting with urosepsis and heart failure
secondary to a severe anemia and neutropenia. Limited experience and resources resulted in a delay in diagnosis.
Genetic studies later confirmed a heterozygous whole gene deletion of RPL35A. Initial treatment was directed
toward correcting the anemia with red blood cell transfusion every 3 to 5 weeks.
Conclusion: Diamond–Blackfan anemia is a rare disease that carries significant morbidity and mortality if not
diagnosed early and managed appropriately. Limited health resources, patient registries, and specialists as seen in
developing countries result in a paucity of knowledge about Diamond–Blackfan anemia in Africa. This case reminds
clinicians about Diamond–Blackfan anemia as a cause for anemia in infants, the limitations in making the diagnosis
in under-resourced health care systems, and the need for standardized treatment protocols applicable to resource-
limited countries.
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Background
Diamond–Blackfan anemia (DBA) is a rare congenital
red blood cell (RBC) aplasia characterized by failed
erythropoiesis, congenital abnormalities, and a predis-
position to malignancy. Also known as one of the rare
groups of inherited bone marrow failure syndromes, this
clinically and genetically heterogeneous condition was
first described by Josephs in 1936 and then as a distinct
entity in 1938 by Diamond and Blackfan [1].
Numerous theories regarding the etiology of DBA have
been proposed. Traditionally, DBA was considered a
ribosomopathy caused by genetic mutations in one of 19
ribosomal proteins affecting ribosome synthesis. More
recently, however, three non-ribosomal gene mutations
have been identified: GATA1 (an erythroid transcription
factor), TSR2 (a gene encoding a direct binding partner
of RPS26) [2, 3], and EPO [4]. The exact pathogenesis
underlying the tissue expression in DBA and predilec-
tion for erythroid defects is not fully understood.
The characteristic hematological features of DBA in-
clude a severe normochromic macrocytic anemia, reticu-
locytopenia, isolated erythroid hypoplasia in the bone
marrow, and an increased erythrocyte adenosine
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deaminase (eADA) [5], erythrocyte “i” antigen, and fetal
hemoglobin (Hb) [6].
The prevalence of DBA in South Africa is not cur-
rently known. Data published from international regis-
tries report an incidence of 1:100,000–200,000 live births
[7, 8]. With no known geographical variance in DBA
and approximately 1,000,000 live births annually in
South Africa, one can estimate between five and ten
cases of children born with DBA every year. Limitations
in access to children’s health care and knowledge around
rare diseases remain a significant challenge in developing
countries and could explain the low incidence of re-
ported cases. Although the anemia can present at any
age, the median age of diagnosis is 12 weeks of age, with
90% of patients presenting with anemia within the first
year [9]. It is therefore essential that DBA be considered
in the workup of any infant presenting with anemia. We
present the first known recorded case of DBA in South
Africa.
Case presentation
A 6-week-old Caucasian girl was admitted to a private
hospital in South Africa with acute onset symptomatic
cardiac failure secondary to anemia. Her parents re-
ported a 1-day history of lethargy, poor feeding, short-
ness of breath, and irritability on a background history
of progressive pallor.
There was no family history of note. Antenatal history
included a low maternal pregnancy-associated plasma
protein A (PAPP-A) level (0.376 IU/L) which resulted in
a high-risk screening protocol for intrauterine growth
restriction (IUGR) and fetal chromosomal anomalies.
Cell-free fetal deoxyribonucleic acid testing from mater-
nal blood excluded aneuploidies for the common triso-
mies [10–12] and subsequent fetal anomaly ultrasound
and echocardiogram scans were all normal. A caesarean
section was performed at 37 weeks for spontaneous
labor, IUGR, and breech presentation. The delivery was
uneventful and apart from a low birth weight of 2465 g,
a healthy baby was discharged 3 days post caesarean sec-
tion as per normal protocol.
On admission to hospital at 6 weeks of age, the baby
under examination was severely anemic, tachycardic,
and lethargic. There were no stigmata of immunocom-
promise, infection, or icterus. The baby weighed 3200 g
with a head circumference of 38 cm.
There were no obvious craniofacial or skeletal abnor-
malities of note and examinations of her other systems
were normal. The preliminary results with normal range
for age in brackets showed a hemoglobin (Hb) level of
3.1 gm/dL (10–18 gm/dL) and a hematocrit of 9% (31–
55%), mean corpuscular volume of 106 fl (85–123 fl),
mean corpuscular Hb concentration 34 g/dL (32–37 g/
dL), reticulocyte production index of 0.0, and an
absolute reticulocyte count of 5.1 × 109/L (20–60 × 109/
L). Her white cell count was low 4.0 × 109/L (5–19.5 ×
109/L) but apart from a low neutrophil count of 0.32 ×
109/L (1–9 × 109/L), the remaining differential count was
normal. Her platelet count was increased 655 × 109/L
(140–420 × 109/L). Her C-reactive protein was margin-
ally raised at 7.7 mg/L (< 5mg/L), and the infective work
up was positive for Escherichia coli cultured from the
urine. Tests for cytomegalovirus, human immunodefi-
ciency virus (HIV), rubella, Epstein–Barr virus, toxoplas-
mosis, herpes simplex virus 1 and 2, and parvovirus B19
were all negative. A diagnosis of E. coli urosepsis was
made. The baby was transfused with leukodepleted irra-
diated red cell concentrate to an Hb level of 10 g/dL and
given goal-directed antibiotics and discharged 6 days
later.
Readmission 14 days later with an anemia (Hb 7.7 g/
dL) and associated reticulocytopenia of 7.0 × 109/L (20–
60 × 109/L) prompted a provisional diagnosis of transient
erythroblastopenia of childhood (TEC), which was made
after infection, HIV, and tuberculosis were excluded.
Three further admissions over the next 3 months for
anemia requiring red cell transfusions and a persistent
neutropenia prompted a bone marrow biopsy (Figs. 1
and 2).
Review of the bone marrow biopsy showed reactive
features with markedly increased megakaryopoiesis and
significant lymphocytic infiltrate. Flow cytometry dem-
onstrated the infiltrate to consist of T cells, mature B
cells, and hematogones. An absence of red cell precur-
sors and immunohistochemical glycophorin stain on the
bone marrow trephine confirmed a pure red cell aplasia.
Due to the unavailability of molecular and eADA test-
ing in South Africa, specimens for molecular testing
were sent to Oxford, UK, for identification of a possible
heterozygous pathogenic variant in one of the genes as-
sociated with DBA. A multigene panel using the
Fig. 1 Bone marrow trephine hematoxylin and eosin stain.
Normocellular trephine showing normal megakaryopoiesis
and granulopoiesis
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Multiplex Ligation-dependent Probe Amplification kit
(MRC-Holland) confirmed a heterozygous whole gene
deletion of RPL35A. In addition, dried plasma was sent
to Duke University Medical Center, USA, to exclude ad-
enosine deaminase 2 deficiency.
Once the diagnosis of DBA was made, the non-
standardized management and limited experience in man-
aging DBA in South Africa resulted in inconsistencies in
opinion in the optimal early management of the case.
Controversies around Hb transfusion threshold, optimal
Hb target, frequency of transfusions, and timing and dos-
age of corticosteroid treatment and hematopoietic stem
cell transplantation (HSCT) resulted in different opinions
from different specialist practitioners.
Together with input from international DBA specialists
managing large numbers of patients with DBA, the initial
hematopoietic management in this case was directed to-
ward correcting the anemia with transfusions every 3–5
weeks with irradiated leukodepleted RBC concentrate. A
transfusion threshold of 8 g/dL was used and a volume of
10–15ml/kg transfused on each visit. Planned iron chela-
tion therapy to prevent transfusional hemosiderosis will
be delayed until approximately 170–200ml/kg of trans-
fused red packed cells has been given. A planned trial of
corticosteroids will be given at 1 year of age.
At follow-up at 6 months of age, the baby was stable
requiring red cell concentrate infusion therapy every 3–
4 weeks. Persistence in the neutropenia was noted, with
no changes in the other cell lineages. Her current ferritin
level is 573 μg/L and a total of 90 ml/kg of red packed
cells has been transfused, thus, iron chelation therapy
has not yet been instituted. Apart from a delay in gross
motor development and growth (weight and height), all
other parameters and development are within normal
limits.
Discussion
DBA is a rare cause of aplastic anemia and the main dif-
ferential diagnosis of anemia due to decreased RBC
production includes TEC, infections, and other genetic
causes of bone marrow failure. These are, however, usu-
ally associated with additional cytopenias and include
Shwachman–Diamond syndrome, Fanconi’s anemia, dys-
keratosis, and Pearson marrow pancreas syndrome.
Other acquired causes include aplasia associated with
viral infections, drugs, autoimmune conditions, malig-
nancies, and, rarely in adults, a thymoma should be con-
sidered [13].
RPL35A is a gene that encodes a 60S large ribosomal
subunit protein and accounts for 3.3% of cases of DBA
identified with a gene mutation [6]. It was described by
Farrar et al. [14] in 2008 and was the first large riboso-
mal subunit protein defect directly linked to DBA in
humans. Although a pure red cell aplasia is typical of
DBA, RPL35A mutations may have an associated neutro-
penia [9]. To date, mutations in 19 ribosomal genes
(RPS7, RPS10, RPS15A, RPS17, RPS19, RPS24, RPS26,
RPS27, RPS28, RPS29, RPL5, RPL11, RPL15, RPL18,
RPL26, RPL27, RPL31, RPL35, RPL35A) and 3 non-
ribosomal genes (GATA1, TSR2, EPO) have been impli-
cated in DBA [9].
The criteria used to establish the diagnosis of DBA
have evolved. The current criteria proposed by Vlachos
et al. [8] use clinical, histological, biochemical, and gen-
etic parameters. Using the current proposed guidelines,
there are a number of obstacles to making the diagnosis
of DBA in South Africa and other countries in Africa.
This is largely due to limited resources, tests, and health
care services available. In addition, the historical access
to health care and worker migration may influence
obtaining an accurate family history about inheritance
patterns of diseases. In children, TEC is the main differ-
ential diagnosis which must be excluded before making
the diagnosis of DBA. Both i-RBC antigen testing and
eADA activity testing which are used to differentiate
TEC from DBA are not freely available in Africa. In
addition, both genetic testing for DBA and eADA are
not available in South Africa, and although bone marrow
biopsies and histopathology are available, it is limited to
a few of the larger centralized health institutions.
DBA currently has no curative treatment option.
Mainstay treatment options to correct the anemia in-
clude chronic RBC transfusions, corticosteroid therapy,
and HSCT [10, 15, 16]. Gene therapy, although still
novel, does provide a theoretical cure to DBA. Increas-
ing interest in gene therapy using viral vectors [6, 17]
and novel gene editing tools CRISPR/Cas9 [18] could
change current treatment protocols. Debnath et al. [6]
recently reported successfully correcting the anemia in a
mouse with DBA using a lentiviral vector with cellular
promoters.
Current guidelines, however, are to initially treat the
anemia with red cell transfusions until 1 year of age
Fig. 2 Bone marrow glycophorin. Absence of red blood
cell precursors
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when a trial of steroids should be done [15]. Some au-
thorities propose an earlier trial of steroids (6 months of
age) in certain cases such as the possibility of no access
to safe blood products. There are, however, concerns
around growth stunting and neuromotor development
with early use of corticosteroids [19, 20]. Despite 70–
80% of patients initially responding to corticosteroids,
only half remain on corticosteroid doses low enough to
minimize toxicity [10]. Approximately 20% go into re-
mission and the remaining 40% remain transfusion
dependent [11]. Apart from corticosteroids, there are
limited case reports of remission or improvement in Hb
level using leucine [13, 21] or metoclopramide [12].
Conclusion
DBA although a rare cause for red cell aplasia needs to
be considered in the differential diagnosis especially in
infants. The diagnosis of DBA in this patient subse-
quently highlighted not only the difficulty in diagnosing
DBA in a resource-limited setting, but also the lack of
consensus in treating DBA. This case highlights the need
for the establishment of a protocolized workup for
infants with persistent anemia of unknown cause that in-
cludes rare genetic causes. Limited access to investiga-
tions needed to make the diagnosis of DBA using
current diagnostic criteria needs to be reviewed due to
the inaccessibility in Africa of some of the specialized
tests. Familiarization with international treatment guide-
lines is important in the treatment of rare diseases but
local guidelines need to be established.
Lastly, this case highlights the paucity of knowledge
around DBA in Africa and the need for further research
into the epidemiology of DBA in Africa and the estab-
lishment of local treatment guidelines.
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